Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 9 ~3 ~% c6 `, { L. Y" y! r
) y+ M+ Q8 @, v- Z
, ?5 C- {/ S& p Q* ISub-category:% @3 ^# M; X# g1 ?, Y& P" W
Molecular Targets 3 }8 w! ~" T) W# Z$ c$ U
# P" o& H1 G# {8 W6 r1 j
# ]" {' j+ k7 b {% k! MCategory:7 G/ s0 m Q5 H$ K; L. t
Tumor Biology 5 n0 d" P+ i, p+ Q) c8 Z
; `/ S; _* A% y8 U) Y6 H3 q$ z( D( O
Meeting:
& X! F' Y0 j) d$ U4 Y `6 v2011 ASCO Annual Meeting
6 A; L8 @0 q1 p+ Y/ H+ O
5 s. B& T& w2 C9 m( L+ d- a. o/ |+ _: C$ R, w1 t( r
Session Type and Session Title:$ d6 f6 u3 i4 z3 G% o6 X* |
Poster Discussion Session, Tumor Biology $ D* `2 [ x1 p: M% m0 r
$ S! _+ S" ?+ t% i
8 ]* O4 M9 n/ o% p+ |- F) zAbstract No: J l% \6 j+ z- [& t r9 c# f" C
10517 4 y; N4 C4 o9 T
5 S C8 j5 A' g+ T4 ~/ y* m, F3 @
Citation:
1 R+ R; L/ G) l' HJ Clin Oncol 29: 2011 (suppl; abstr 10517) ' G& G! p" \. [
/ ?4 B t6 t$ F
~% R, f' u: R* s IAuthor(s):7 `, h* x9 s0 u1 K4 E- w
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 7 \4 W! }4 _! Z" i4 g4 {# x5 p
' y2 a+ t0 K" `/ p& D/ l( n
3 y: y# g, a0 _7 C1 ~
, A& b4 M- ^. ]* ~9 t( Z& B5 d# A5 SAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.' O5 G& ]; [1 |( R5 g0 C7 _
. S) ?0 g0 W3 s2 U' ^* Z
Abstract Disclosures) l* S' a2 O/ e/ X( P* C* l
7 G, ?. l, n5 N/ L# q
Abstract:& t. M/ i7 H2 b H
4 \* R3 J9 p, y, U7 ]
( f) P; [* ^0 q% j h
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.9 v7 j7 ^0 ~* J! w
2 M. C2 p& h. b [
/ U `, y, Y& _. N: H |
显身卡
